Introduction
Methods
Search and selection
Inclusion and exclusion criteria
Data extraction and analysis
Risk of bias
Results
Study selection
References | Duration of randomized assessment period | Age, years | Active treatment group(s) | Number randomized (ratio, active[s]: placebo) | Principal symptom-based efficacy outcome versus placebo at study endpoint or last assessment | HRQoL/functional outcomes: significant effect(s) of medication(s) versus placebo at study endpoint or last assessment | HRQoL/functional outcomes: other reported comparisons of medication(s) versus placebo |
---|---|---|---|---|---|---|---|
Short-term studies—stimulant medications | |||||||
Banaschewski et al. 2013 [15] | 7 weeks | 6–17 | LDX (30, 50 or 70 mg/day, optimized); OROS-MPH reference (18, 36 or 54 mg/day, optimized) | 336 (1:1:1) | ADHD-RS-IV total score (effect sizes LDX, 1.80***; OROS-MPH, 1.26***) | CHIP-CE:PRFa Achievement (effect sizes LDX, 1.280***; OROS-MPH, 0.912***), Risk Avoidance (1.079***; 0.948***), Resilience (0.421**; 0.398*), Satisfaction (0.365*; 0.349*) WFIRS-P total score (effect size LDX, 0.924***; OROS-MPH, 0.772***), Family (0.730***; 0.646***), Learning and School (1.249***; 0.910***), Social Activities (0.643***; 0.642***), Risky Activities (0.640***; 0.414*), Life Skills (OROS-MPH, 0.348*), Child’s Self-Concept (OROS-MPH, 0.362*) | CHIP-CE:PRFa Comfort (effect sizes LDX, 0.003NS; OROS-MPH, 0.181NS) WFIRS-P Life Skills (effect size LDX, 0.241NS), Child’s Self-Concept (LDX, 0.264NS) |
Findling et al. 2011 [45] | 4 weeks | 13–17 | LDX (30, 50 or 70 mg/day, forced titration) | 314 (1:1:1:1) | ADHD-RS-IV total score (LDX 30 mg**, 50 mg**, 70 mg**) | None | YQOL-R overall scoreNS, Sense of SelfNS, Social RelationshipsNS, EnvironmentNS, General QoLNS, contextual itemsNS, item 57NS
|
Greenhill et al. 2006 [50] | 7 weeks | 6–17 |
d-MPH-ER (5, 10, 15, 20, or 30 mg/day, optimized) | 103 (1:1) | CADS-T total score (effect size 0.79***) | CHQ-PF50a Psychosocial summary*** | CHQ-PF50a Physical summaryNS
|
Wilens et al. 2010 [99] | 2 weeks | 6–12 | TD-MPH (20 mg, forced titration) | 30 (1:1 crossover) | ADHD-RS-IV total score*** | Investigator-rated BSFQa total score** | Patient-rated BSFQNS,a
|
Abikoff et al. 2007 [1] | 4 weeksb
| 3–5.5 | MPH (1.25, 2.5, 5.0 or 7.5 mg t.i.d., optimized) | 114 (1:1) | SNAP-IV parent–teacher composite score (effect size 1.20***) [49] | SCS-T total score (effect size 0.39*) | SCS-P total score (effect size 0.13NS) SSRS-P Total Social Skills (effect size 0.14NS) |
Short-term studies—stimulant and non-stimulant medications | |||||||
Newcorn et al. 2008 [68] | 6 weeks | 6–16 | ATX (0.8–1.8 mg/kg/day) or OROS-MPH (18–54 mg/day) | 516 (3:3:1) | ADHD-RS-IV total score (effect sizes ATX, 0.6**; OROS-MPH, 0.8***) | CHQa,c Psychosocial summary (ATX,*,d OROS-MPH*,d) | |
Short-term studies—non-stimulant medications | |||||||
Hervas et al. 2014 [51] | 10 weeks (children) or 13 weeks (adolescents) | 6–17 | GXR (1–7 mg/day, optimized); ATX reference (0.5–1.4 mg/kg/day) | 338 (1:1:1) | ADHD-RS-IV total score (effect sizes GXR, 0.76***; ATX, 0.32*) | WFIRS-P total score (effect sizes GXR, 0.44**; ATX, 0.28*), Learning and School (0.42**; 0.32*), Family (GXR, 0.38**), Social Activities (GXR, 0.45**) | WFIRS-P Family (effect size ATX, 0.16NS), Social Activities (ATX, 0.21NS), Life Skills (GXR, 0.23NS; ATX, 0.16NS), Child’s Self-Concept (0.09NS; 0.15NS), Risky Activities (0.21NS; 0.14NS) |
Wilens et al. 2013 [100]e
| 9 weeks | 6–17 | Adjunctive GXR (a.m. or p.m., 1–4 mg/day, optimized) to current long-acting stimulant | 461 (1:1:1) | ADHD-RS-IV total score (effect sizes a.m., 0.377**; p.m., 0.447***) [98] | Parent-rated BSFQa score (a.m.*** and p.m.** dosing) | Participant-rated BSFQa FeelingNS, BehaviourNS
|
Wilens et al. 2015 [101] | 13 weeks | 13–17 | GXR (1–7 mg/day, optimized) | 314 (1:1) | ADHD-RS-IV total score (effect size 0.52***) | None | WFIRS-P Learning and School (effect size 0.22NS), Family (0.11NS) |
Stein et al. 2015 [86] | 8 weeks | 6–12 | GXR (a.m. or p.m., 1–4 mg/day, optimized) | 333 (1:1:1) | ADHD-RS-IV total score (overall effect size 0.77***) [70] | WFIRS-P total score (overall effect size 0.448***), Family (0.528***), Learning and School (0.463***), Academic Performance (0.413**), Social Activities (0.419***), Risky Activities (0.337*) | WFIRS-P Behaviour in School (overall effect size 0.389NS), Life Skills (0.166NS), Child’s Self-Concept (0.052NS) |
Wehmeier et al. 2011 [94]f
| 9 weeks | 6–17 | ATX (1.2 mg/kg/day, fast or slow forced titration)g
| 181 (1:1:1) | SNAP-IV ADHD subscale score (overall effect size 0.72***) [38] | KINDL-R total score (overall effect size 0.377*), Physical Well-Being (−0.390*), Emotional Well-Being (0.318*), Self-Esteem (0.590***), Family (0.395*), Friends (0.387*) | KINDL-R School (overall effect size 0.248NS) |
Svanborg et al. 2009 [91] | 10 weeks | 7–15 | ATX (1.2 mg/kg/day, forced titration)h
| 99 (1:1) | Parent-rated ADHD-RS-IV total score*** [90] | CHIP-CE:PRFa Achievement*, Risk Avoidance* | CHIP-CE:PRFa ResilienceNS, SatisfactionNS and ComfortNS
JTJA total scoresNS,i and domainsNS
|
Dell’Agnello et al. 2009 [37]f
| 8 weeks | 6–15 | ATX (1.2 mg/kg/day, forced titration) | 139 (3:1) | SNAP-IV ADHD subscale score*** | CHIP-CE:PRFa Risk Avoidance* | CHIP-CE:PRFa AchievementNS, SatisfactionNS, ResilienceNS, ComfortNS
|
Escobar et al. 2009 [42] | 12 weeks | 6–15 | ATX (1.2 mg/kg/day, forced titration) | 151 (2:1) | Parent-reported, investigator-rated ADHD-RS-IV total score (effect size 0.82***) [67] | CHIP-CE:PRFa Risk Avoidance (effect size 0.557***), Achievement (0.286*) CHIP-CE:SRF/AEa Risk Avoidance (effect size 0.387**) | CHIP-CE:PRFa Satisfaction (effect size 0.033NS), Comfort (0.163NS), Resilience (0.113NS) CHIP-CE:SRF/AEa (self-reported) Satisfaction (effect size 0.137NS), Comfort (0.104NS), Resilience (0.016NS), Achievement (0.085NS) |
Brown et al. 2006 [17] | 7 weeks | 8–12 | ATX (0.8–1.8 mg/kg/day, optimized) | 153 (2:1) | ADHD-RS-IV teacher-rated version total score (effect size 0.62**) | Frequency of CHQ-PF50a Psychosocial summary response* | CHQ-PF50a Psychosocial summary (effect size 0.32NS) APRS total score (effect size 0.31NS) |
Michelson et al. 2001 [66] | 8 weeks | 8–18 | ATX (0.5, 1.2 or 1.8 mg/kg/day, forced titration) | 297 (1:2:2:2) | Parent-rated ADHD-RS-IV total score (0.5 mg/kgNS; 1.2 mg/kg***; 1.8 mg/kg***) | CHQ-PF50a,c Psychosocial summary* (all doses) | CHQ-PF50a Physical summaryNS (all doses) |
Long-term studies—stimulant medications | |||||||
Banaschewski et al. 2014 [14] | 6 weeks (withdrawal after 6 months) | 6–17 | LDX (30, 50 or 70 mg/day, optimized) | 153 (1:1) | Treatment failure (≥50% increase in ADHD-RS-IV total score and ≥2-point increase in CGI-S score)***; ADHD-RS-IV total score (effect size 1.493***) | CHIP-CE:PRFa Achievement (effect size 0.696***), Risk Avoidance (0.829***), Satisfaction (0.636***) WFIRS-P total score (0.908***), Family (0.859***), Learning and School (0.716***), Risky Activities (0.506**) | CHIP-CE:PRFa Resilience (effect size 0.275NS), Comfort (0.348NS) WFIRS-P Life Skills (0.228NS), Child’s Self-Concept (0.203NS), Risky Activities (0.197NS) |
Long-term studies—non-stimulant medications | |||||||
Michelson et al. 2004 [65] | 6 months (withdrawal) | 6–15 | ATX (1.2–1.8 mg/kg/day, optimized) | 416 (2:1) | Relapse avoidance (ADHD-RS-IV total score ≥ 90% of baseline value and ≥ 2-point increase in CGI-S score)**; ADHD-RS-IV total score*** | CHQa,c Psychosocial summary* | None |
References | Duration of randomized assessment period | Age, years | Active treatment group(s) | Number randomized (ratio, active[s]: placebo) | Principal symptom-based efficacy outcome versus placebo at study endpoint or last assessment | HRQoL/functional outcomes: significant effect(s) of medication(s) versus placebo at study endpoint or last assessment | HRQoL/functional outcomes: other reported comparisons of medication(s) versus placebo |
---|---|---|---|---|---|---|---|
Short-term studies—stimulant mediations | |||||||
Huss et al. 2014 [52] | 9 weeksa
| 18 − 60 | MPH-LA (40, 60 or 80 mg/day, fixed) | 725 (1:1:1:1) | ADHD-RS-IV total score (effect size 0.55***) | SDS total score (effect size 0.39*) | None (SDS subscales not reported) |
Adler et al. 2013 [3]b
| 10 weeks | 18 − 55 | LDX (30, 50 or 70 mg/day, optimized) | 161 (1:1) | ADHD-RS-IV total score (effect size 0.94***) [4] | AIM-A Performance and Daily Functioning (effect size 0.93*), Impact: Daily Interference (0.62*), Impact: Bother/Concern (0.57*), Relationships/Communication (0.31*), Living with ADHD (0.79***), General Well-Being (0.70***), Overall QoL questions 1 (0.29*) and 4 (0.44***) | AIM-A overall QoL questions 2NT and 3NT
AAQoL total score, Life ProductivityNT, Psychological HealthNT, Life OutlookNT, RelationshipsNT
|
Casas et al. 2013 [25] | 12 weeks | 18–65 | OROS-MPH (54 or 72 mg/day, fixed) | 279 (1:1:1) | CAARS-O:SV total score (effect sizes 54 mg, 0.20NS; 72 mg 0.49**) | AIM-A Performance and Daily Functioning (54 mg**, 72 mg***), Impact: Daily Interference (54 mg*, 72 mg*), Relationships/Communication (72 mg**), Living with ADHD (72 mg*), General Well-Being (54 mg*) | AIM-A Relationships/Communication (54 mgNS), Living with ADHD (54 mgNS), General Well-Being (72 mgNS), Impact: Bother/Concern (54 mgNS, 72 mgNS); overall QoL questions not reported SDS totalNS and subscaleNS scores |
Rösler et al. 2013 [82] | 5 weeks | 18–65 | OROS-MPH (18, 36 or 72 mg/day, fixed) | 402 (1:1:1:1) | CAARS-O:SV total score (18 mg*, 36 mg*, 72 mg***) [64] | SDS total score (18 mg**, 36 mg*, 54 mg**), Work (18 mg**, 54 mg**), Social Life (18 mg*, 36 mg**, 54 mg***), Family Life (18 mg*, 54 mg**) | SDS Work (36 mgNS), Family Life (36 mgNS) Q-LES-QNS
|
Weiss et al. 2012 [96] | 20 weeks | 18–66 |
d-AMP (5–20 mg b.i.d; both groups also received CBT) | 48 (1:1)c
| ADHD-RS-IV total scoreNS
| None | SDSNS (subscales not reported) |
Retz et al. 2012 [78] | 8 weeks | ≥18 | MPH-ER (40, 60, 80 or 120 mg b.i.d., optimized) | 162 (1:1) | WRAADDS total score (effect size 0.54***) | SDS total score (effect size 0.40*) | None (SDS subscales not reported) |
7 weeks | 18–55 | MAS-XR3 (12.5, 25, 50 or 75 mg/day, optimized) | 274 (1:1) | ADHD-RS-IV total score*** | AIM-A Living with ADHD***, General Well-Being***, Performance and Daily Functioning***, Relationships/Communication***, Impact: Bother/Concern*, Impact: Daily Interference**, overall QoL questions 1*** and 4*** | AIM-A overall QoL questions 2NT and 3NT
| |
Short-term studies—non-stimulant medications | |||||||
Goto et al. 2013 [48] | 10 weeks | ≥18 | ATX (40, 80, 105 or 120 mg/day, optimized) | 391 (1:1) | CAARS-I:SV total score (effect size 0.55***) | AAQoL total score**, Life Outlook*, Life Productivity*** and Relationships** | AAQoL Psychological HealthNS
|
Durell et al. 2013 [40] | 12 weeks | 18–30 | ATX (40, 80 or 100 mg b.i.d., optimized) | 445 (1:1) | CAARS-I:SV total score (effect size 0.4***) | AAQoL total score (effect size 0.3**), Relationships*, Life Productivity**, Psychological Health* | AAQoL Life OutlookNS
SASS total scoreNS
|
Lee et al. 2014 [55] | 10 weeks | ≥18 | ATX (40–120 mg/day) | 74 (1:1) | CAARS-I:SV total score*** | None | AAQoL total scoreNS, Psychological HealthNS, Life OutlookNS, Life ProductivityNS, Quality of RelationshipsNS
|
Adler et al. 2009a [5]d
| 14 weeks | 18–65 | ATX (40, 80 or 100 mg/day, optimized) | 442 (1:1) | CAARS-I:SV total score (effect size 0.47***) | AAQoL total score (effect size 0.24*), Psychological Health* | AAQoL Life OutlookNS, Life ProductivityNS, Quality of RelationshipsNS
|
Manor et al. 2012 [59] | 6 weeks | 18–50 | Metadoxine (1.4 g/day) | 120 (1:1) | CAARS-I total score (effect size 0.4*) | AAQoL total score* | None (AAQoL domains not reported) |
Riahi et al. 2010 [79] | 6 weeks | Adults | Reboxetine (4 mg b.i.d.) | 46 (1:1) | CAARS-S:SV total score (effect size 0.04NS) | GAF score*** | None |
Long-term studies—non-stimulant medications | |||||||
Wietecha et al. 2012 [97]e
| 24 weeks | ≥18 | ATX (60, 80 or 100 mg/day, optimized) | 502 (1:1) | CAARS-I:SV total score (effect size 0.57***) | DAS Affectional Expression* PSI Parent Domain Depression*, Life Stress* | DAS Total Dyadic AdjustmentNS, Dyadic ConsensusNS, Dyadic SatisfactionNS, Dyadic CohesionNS
PSI Total StressNS, Child Domain TotalNS, Parent Domain TotalNS
APQ (Patient)NS (all domains) PSCSNS (all domains) FAM-IIINS (all domains) |
Adler et al. 2009b [6] | 6 months | 18–54 | ATX (25, 40, 80 or 100 mg/day, optimized) | 501 (1:1) | AISRS total score** | AAQoL total score**, Life Productivity**, Psychological Health*, Quality of Relationships* | AAQoL Life OutlookNS
|
Adler et al. 2008 [7] | 6 months | 18–50 | ATX (40, 80 or 100 mg/day, flexible) | 410 (2:1) | CAARS-S:SV total score*,f
| AAQoL Life Outlook* DBS (observer reported subset, n = 252)* | AAQoL total scoreNS, Life ProductivityNS, RelationshipsNS, Psychological HealthNS
EWPS total scoreNS,f
DBS (self-reported)NS
|
Patients, medications and outcomes assessed
Generic (rater) | ADHD-specific (rater) | ||
---|---|---|---|
Studies in children and adolescents | |||
HRQoL | CHIP-CE:PRF (parent) – 5 studies CHQ-PF50 (parent)a—5 studies YQOL-R (patient)—1 study [45] KINDL-R (parent)—1 study [94] JTJA (patient)—1 study [91] CHIP-CE:SRF/AE (patient)—1 study [42] | ||
Functional impairment | SCS-P/T (parent/teacher); SSRS-P/T (parent/teacher)—1 study [1] APRS (teacher)—1 study [17] | WFIRS-P (parent)—5 studies | |
Studies in adults | |||
HRQoL | Q-LES-Q (patient)—1 study [82] | AAQoL (patient)—8 studies | |
Functional impairment with HRQoL element | AIM-A (patient)—3 studies | ||
Functional impairment | SDS (patient)—5 studies GAF (investigator)—1 study [79] DBS (patient or observer)—1 study [7] EWPS (patient)—1 study [7] Various family functioning measures (patient)b—1 study [97] |